NCT02728089View on ClinicalTrials.gov

Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)

PHASE3CompletedINTERVENTIONAL

Enrollment

115

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

September 5, 2017

Study Completion Date

September 5, 2017

Conditions

Urinary Tract Infection (UTI)Complicated Urinary Tract InfectionPyelonephritisUncomplicated Pyelonephritis

Interventions

DRUG

MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)

MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02728089 - Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) | Biotech Hunter | Biotech Hunter